Haematologica, Vol 92, Issue 7, 974-977 doi:10.3324/haematol.11051
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Germing, U.
Right arrow Articles by Bennett, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Germing, U.
Right arrow Articles by Bennett, J. M.

Myelodysplastic Syndromes

Chronic myelomonocytic leukemia in the light of the WHO proposals

Ulrich Germing, Corinna Strupp, Sabine Knipp, Andrea Kuendgen, Aristoteles Giagounidis, Barbara Hildebrandt, Carlo Aul, Rainer Haas, Norbert Gattermann, John M. Bennett

From the Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany (UG, CS, SK, AK, RH, NG); Department of Human Genetics, Heinrich-Heine-University, Düsseldorf, Germany (BH); Department of Hematology, Oncology and Clinical Immunology, St. Johannes Hospital, Duisburg, Germany (CA); University of Rochester Medical Center, USA (JMB)

Correspondence: Ulrich Germing, Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Moorenstr. 5, 40225 Düsseldorf, Germany. E-mail: germing{at}med.uni-duessel-dorf.de

The WHO classification moved CMML to myeloproliferative/myelodysplastic disorders, and defined CMML I and CMML II according to medullary and peripheral blast count. To confirm these proposals, we analyzed 266 patients with CMML I and 73 patients with CMML II. Median survival time was 20 months for CMML I, and 15 months for CMML II (p<0.005). The cumulative risk of AML evolution differed between patient groups (p=0.001). No conclusive differences in clinical, morphologic, hematologic or cytogenetic parameters were found. These data support the WHO proposals for the classification of CMML.

Key words: myelodysplastic syndromes, myeloproliferative syndromes, CMML, prognosis, WHO classification.




This article has been cited by other articles:


Home page
 BloodHome page
J. W. Vardiman, J. Thiele, D. A. Arber, R. D. Brunning, M. J. Borowitz, A. Porwit, N. L. Harris, M. M. Le Beau, E. Hellstrom-Lindberg, A. Tefferi, et al.
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
Blood, July 30, 2009; 114(5): 937 - 951.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
B. Suh, T. S. Park, J. S. Kim, J. Song, J. Kim, J.-H. Yoo, and J. R. Choi
Chronic Myelomonocytic Leukemia with der(9)t(1;9)(q11;q34) as a Sole Abnormality
Ann. Clin. Lab. Sci., January 1, 2009; 39(3): 307 - 312.
[Abstract] [Full Text] [PDF]